论文部分内容阅读
目的:分析并研究血塞通注射液治疗早期脑梗死患者的临床治疗结果。方法:选取2011年3月-2013年4月期间医治早期脑梗死患者80例作为研究人员,按数字法将其随机分成两组(A、B),每组40例,均入院后给予常规治疗,B组患者在此基础上借助低分子右旋糖酐进行临床治疗,A组患者在此基础上借助血塞通注射液进行治疗,观察两组患者临床医治成果。结果:临床医治成果表明,两组患者的临床治疗总有效率(95.0%vs80.0%)、临床医治后神经功能缺损评分(14.53±8.44vs 18.26±8.75)、不良反应发生率(7.5%vs 25.0%)均存在明显性临床差别,P<0.05,具备统计学意义。结论:借助血塞通注射液治疗早期脑梗死患者,临床效果显著,可提高患者临床治愈率,降低不良反应发生率,值得推广使用。
Objective: To analyze and study the clinical results of Xuesaitong injection in the treatment of patients with early cerebral infarction. Methods: Eighty patients with early-stage cerebral infarction who were treated in March 2011-April 2013 were selected and randomly divided into two groups (A and B) according to the digital method. Each group was given 40 cases of conventional cerebral infarction On the basis of this, group B patients were treated with low molecular weight dextran. Patients in group A were treated with Xuesaitong injection on this basis, and the clinical outcomes of the two groups were observed. Results: The results of clinical treatment showed that the total effective rate of clinical treatment (95.0% vs80.0%), clinical neurological deficit score (14.53 ± 8.44 vs 18.26 ± 8.75), adverse reaction rate (7.5% vs 25.0%) had significant clinical differences, P <0.05, with statistical significance. Conclusion: With Xuesaitong injection for early cerebral infarction patients, the clinical effect is significant, which can improve the clinical cure rate of patients and reduce the incidence of adverse reactions, which is worth promoting the use of.